## Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing

Taihang Shao<sup>1*</sup>, Mingye Zhao<sup>1*</sup>, Leyi Liang<sup>1</sup>, Wenxi Tang<sup>1,2#</sup>

1 Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China, 211198<br>
2 Department of Public Affairs Management, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China, 211198

*These authors contributed equally to this work; <br>
#Corresponding authors

PS: Codes in this repository are used to reproduce this analysis.<br>
Original data are also provided in this repository.<br>

Journal: BioDrugs<br>
DOI: https://doi.org/10.1007/s40259-023-00586-6

Any questions or technical consulting:<br>
Email: cpu_sth@stu.cpu.edu.cn


<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>
<br>

#### A copy of this article can be obtained through the following QR code<br>


![biodrugs-s40259-023-00586-6](https://user-images.githubusercontent.com/101975842/223887115-0ab9bcf4-c999-4a98-bd0e-f59554c2075a.png)
